ArticleMedComm2025

A Dose-Tailored Anti-Plasma Cell Regimen Lowers the Mortality of Late-Stage Cardiac Amyloidosis.

Yun Ti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.